July 14, 2022

Pfizer’s Xalkori® (crizotinib) has received a new indication to treat unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors (IMT) in patients who are at least one year of age.

  • IMTs are a rare form of tumor that, while usually noncancerous, can cause significant health problems depending on their location.
  • Xalkori first received FDA approval in 2011 and is also approved to treat certain patients who have non-small cell lung cancer or systemic anaplastic large cell lymphoma.
  • Recommended dosing for IMT treatment is:
    • Adults: 250mg by mouth twice daily until disease progression or unacceptable toxicity.
    • Pediatric Patients: 280mg/m2 of body surface area taken by mouth twice daily until disease progression or unacceptable toxicity.
August 18, 2022

U.S. FDA Approves First Cetrotide Generic

Read More
August 17, 2022

Zynteglo Approved as Gene Therapy for Rare Blood Disorder

Read More